Outcome of plasmapheresis in myasthenia gravis: Delayed therapy is not favorable
Authors:
- 14 March 2011
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 43 (4) , 578-584
Abstract
Introduction: The purpose of this study was to compare the in‐hospital mortality and complication rates after early and delayed initiation of plasma exchange (PLEX) in patients with myasthenia gravis (MG). Methods: Our cohort was identified from the Nationwide Inpatient Sample database for the years 2000 through 2005. Early treatment was defined as therapy with PLEX administered within the first 2 days from hospital admission. Univariate and multivariate analyses were employed. Results: One thousand fifty‐three patients were treated and included in the analysis. A delay in receiving PLEX was associated with higher mortality (6.56% vs. 1.15%, P< 0.001) and increased complications (29.51% vs. 15.29%, P< 0.001). Adjusted analysis showed increased mortality [odds ratio (OR) 2.812; 95% confidence interval (CI) 1.119–7.069] and complications (OR 1.672; 95% CI 1.118–2.501) with delayed PLEX therapy. Conclusions: Delaying PLEX therapy for MG by more than 2 days after admission may lead to higher mortality and complication rates, and thus prompt therapy is warranted. Muscle Nerve 43: 578–584, 2011Keywords
This publication has 24 references indexed in Scilit:
- Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols☆European Journal of Cardio-Thoracic Surgery, 2009
- MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravisJournal of the Neurological Sciences, 2007
- Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravisJournal of Neurology, 2007
- Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresisJournal of Clinical Apheresis, 2007
- Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United StatesCirculation, 2005
- Soluble Adhesion Molecules and Cytokines in Patients with Myasthenia Gravis Treated by Plasma ExchangeBlood Purification, 2000
- Relationship of Symptom-Onset-to-Balloon Time and Door-to-Balloon Time With Mortality in Patients Undergoing Angioplasty for Acute Myocardial InfarctionJAMA, 2000
- Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisisNeurology, 1999
- Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravisAnnals of Neurology, 1997
- Assessment of plasmapheresis [RETIRED]Neurology, 1996